QHSLab Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Troy Grogan

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	9.3yrs
CEO ownership	31.9%
Management average tenure	no data
Board average tenure	3.6yrs

Recent management updates

Recent updates

CEO

Troy Grogan (47 yo)

9.3yrs

Tenure

Mr. Troy James Grogan has been Chief Executive Officer and Chairman of the Board at QHSLab, Inc. (formerly known as USA Equities Corp.) since June 2016 and also serves as its President. Mr. Grogan has a ba...

Board Members

Name	Position	Tenure	Compensation	Ownership
Troy Grogan	CEO, CFO	9.3yrs	no data	31.95% $ 402.3k
Reza Yavari	Member of Scientific Advisory Board	no data	no data	no data
Frank Lichtenberger	Member of Medical & Scientific Advisory Board	3.6yrs	no data	no data
Bjorn Herman	Member of Medical & Scientific Advisory Board	3.6yrs	no data	no data
Juan Escobar	Member of Medical & Scientific Advisory Board	3.6yrs	no data	no data
Fredric Pullen	Member of Medical & Scientific Advisory Board	3.6yrs	no data	no data
Alex Mirakian	Member of Scientific & Medical Board of Advisors	no data	no data	no data
Syed A. Rizvi	Member of Scientific Advisory Board	no data	no data	no data
Marcos Sanchez-Gonzalez	Member of Scientific Advisory Board	no data	no data	no data

3.6yrs

Average Tenure

Experienced Board: USAQ's board of directors are considered experienced (3.6 years average tenure).

QHSLab Management

Management criteria checks 1/4

Key information

Recent management updates

USA Equities Corp. Appoints Mike Mangus to Its Advisory and Physician Network Development Team

USA Equities Corp. Announces Management Changes

Recent updates

QHSLab, Inc. Meets the Demand for Updated Mental Health Screening Recommendations from the U.S. Preventive Services Task Force

Qhslab, Inc. Launches A “Long Covid” Digital Health Tool for Primary Care Physicians

USA Equities Corp. announced delayed annual 10-K filing

USA Equities Corp. Introduces AllergiQT™– Quick Test, Further Expanding Market Presence

USA Equities Corp. (OTCPK:USAQ) acquired the method patent, trademark and website associated with AllergiEnd®’s diagnostic and allergen immunotherapy product portfolio from MedScience Research Group, Inc.

USA Equities Corp. Provides Revenue Guidance for the Third Quarter of 2021

USA Equities Corp. (OTCPK : USAQ) entered into an asset purchase agreement to acquire The AllergiEnd® diagnostic and allergen immunotherapy system from MedScience Research Group, Inc.

USA Equities Corp. Appoints Mike Mangus to Its Advisory and Physician Network Development Team

USA Equities Corp. Announces Management Changes

USA Equities Corp Enters into Exclusive Distribution Agreement with MedScience Research Group

USA Equities Corp. announced that it expects to receive $0.5 million in funding

CEO

Tenure

Board Members

Average Tenure